10 mg/ml
Trade Name
IMCIVREE
Solution for injection
Request Type
New Registration
Drug Type
New Drug
Approval Date
SFDA Approved Use
IMCIVREE is intended for the treatment of obesity and the control of hunger associated with genetically confirmed Bardet-Biedl syndrome (BBS), loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children 6 years of age and above.